Trial Profile
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 05 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 09 Jan 2010 New trial record